

# Complementary and Alternative Medicine (CAM) Treatments

MEDICAL POLICY NUMBER: 260

<b>Effective Date:</b> 4/1/2025	COVERAGE CRITERIA .....	2
<b>Last Review Date:</b> 1/2025	POLICY CROSS REFERENCES.....	4
<b>Next Annual Review:</b> 10/2025	POLICY GUIDELINES.....	4
	REGULATORY STATUS.....	6
	CLINICAL EVIDENCE AND LITERATURE REVIEW .....	6
	HEALTH EQUITY CONSIDERATIONS.....	14
	BILLING GUIDELINES AND CODING .....	14
	REFERENCES.....	16
	POLICY REVISION HISTORY.....	21
	APPENDICES.....	21

**INSTRUCTIONS FOR USE:** Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Company reserves the right to determine the application of medical policies and make revisions to medical policies at any time. The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

**SCOPE:** Providence Health Plan, Providence Health Assurance, and Providence Plan Partners as applicable (referred to individually as “Company” and collectively as “Companies”).

## PLAN PRODUCT AND BENEFIT APPLICATION

Commercial

Medicaid/OHP\*

Medicare\*\*

### \*Medicaid/OHP Members

*Oregon:* Services requested for Oregon Health Plan (OHP) members follow the OHP Prioritized List and Oregon Administrative Rules (OARs) as the primary resource for coverage determinations. Medical policy criteria below may be applied when there are no criteria available in the OARs and the OHP Prioritized List.

Complementary and Alternative Medicine: Guideline Note 6

### \*\*Medicare Members

This *Company* policy may be applied to Medicare Plan members only when directed by a separate *Medicare* policy. Note that investigational services are considered “**not medically necessary**” for Medicare members.

## COVERAGE CRITERIA

### Notes:

- Member benefits, which address coverage or non-coverage of specific complementary and alternative medicine treatments, may vary. Member benefit contract language takes precedent over medical policy.
- Services in this policy may exist in other Medical Policies. See [Cross References](#) for guidance.

### Medically Necessary

- I. Therapeutic phlebotomy may be considered **medically necessary** for the management of polycythemia vera, hemochromatosis, iron overload, erythrocytosis, or porphyria (see approved diagnosis codes listed in [Appendix I](#)).
- II. Acupuncture (including dry needling) may be considered **medically necessary** for the management of pain, nausea and/or vomiting, headaches, or migraines (see approved diagnosis codes listed in [Appendices II](#)).

### Not Medically Necessary

- III. Therapeutic phlebotomy is considered **not medically necessary** when criterion I. above is not met.
- IV. Complementary and alternative medicine treatments are considered **not medically necessary** as a treatment of any condition. Treatments of this nature include but are not limited to the following:

- A. Autogenous lymphocytic factor
  - B. Colon hydrotherapy, irrigation, cleansing and lavage
  - C. Intravenous infusion including:
    - 1. Hydrogen peroxide
    - 2. Micronutrients (Myers' cocktail)
    - 3. Ozone treatment (see F.)
    - 4. Vitamin C
  - D. Manual and soft tissue therapies including:
    - 1. Active release techniques®
    - 2. Craniosacral therapy (CST)
    - 3. Cupping
    - 4. Instrument assisted soft tissue mobilization (IASTM), including but not limited to the Graston Technique®
    - 5. TuiNa
  - E. Mesotherapy
  - F. Oxygen therapy, including ozone therapy administered directly to the tissue, intravenously, or intramuscularly
  - G. Placentophagy/placenta capsules
- V. All non-antimicrobial alternative therapies for Lyme disease are considered **not medically necessary**, including but not limited to:
- A. Oxygen and reactive oxygen species
  - B. Energy and radiation
  - C. Heavy metals and chelation
  - D. Nutritional and herbal therapy
  - E. Biological and pharmacological therapy
  - F. Empirical anti-babesiosis therapy in the absence of documentation of active babesiosis
  - G. Anti-Bartonella therapies
  - H. Fever therapy (with or without malaria induction)
  - I. Intravenous immunoglobulin
  - J. Cholestyramine
  - K. Magnesium or bismuth injections
- VI. The following treatments for behavioral health indications are considered **not medically necessary**, including but not limited to (A.-EE.):
- A. Acoustic therapy for anxiety/depression
  - B. Aromatherapy
  - C. Art therapy
  - D. Aura healing
  - E. Brain integration therapy
  - F. Chakra healing
  - G. Color therapy
  - H. Conceptual mind-body techniques
  - I. Crystal healing

- J. Dance/Movement therapy
- K. Equestrian therapy
- L. Faith healing
- M. Feldenkrais method of exercise therapy (i.e. “awareness through movement”)
- N. Gemstone therapy
- O. Guided imagery
- P. Healing/talking circles
- Q. Humor therapy
- R. Hypnosis
- S. Laughter therapy
- T. Music therapy
- U. Pilates
- V. Primal therapy
- W. Psychodrama
- X. Reiki
- Y. Therapeutic touch
- Z. Thought field therapy (TFT) (Callahan Techniques Training)
- AA. Transcendental meditation
- BB. Urban Zen Integrative Therapy
- CC. Virtual reality procedural dissociation
- DD. Weighted blanket for panic disorder
- EE. Yoga

Link to [Evidence Summary](#)

## **POLICY CROSS REFERENCES**

- [Biofeedback and Neurofeedback](#), MP270
- [Chelation Therapy for Non-Overload Conditions](#), MP102
- [Chiropractic Care](#), MP251
- [Hyperbaric Oxygen Therapy](#), MP204
- [Outpatient Physical Therapy](#), MP245
- [Subcutaneous Hormone Pellet Implant](#), MP109

The full Company portfolio of current Medical Policies is available online and can be [accessed here](#).

## **POLICY GUIDELINES**

This policy may be primarily based on the following Center for Medicare and Medicaid Services (CMS) guidance resources:

- National Coverage Determinations (NCD): Acupuncture for Chronic Lower Back Pain (cLBP)<sup>1</sup>

## Complementary and Alternative Medicine

Complementary and alternative medicine (CAM) are approaches to care that are not in the mainstream stand of care approach.<sup>2</sup> They may be practiced by those who hold medical degrees and who might also practice standard, mainstream, allopathic, or Western medicine. In addition, those who are healthcare providers with other licensure (behavioral therapist, physical therapist, psychologist, or others) may also be practitioners of CAM. Complementary treatments are those that are used along with standard medical treatments but are not themselves considered to be standard treatment. Alternative treatments are those that are used instead of standard treatments and may intend to replace mainstream approaches. Often times, treatment may not be easily categorized in one type or another. Treatments are commonly focused on a behavioral health intervention, cancer treatment, or pain management for those with chronic conditions.<sup>3</sup> A 2012 National Health Interview Survey, which was conducted by the National Center for Health Statistics, part of the Centers for Disease Control and Prevention, found that 33.2 percent of adults in the United States aged 18 years and over and 11.6 percent of children age 4 to 17 years used some form of complementary health approach in the previous 12 months.<sup>4</sup> The percentages of adults and children using complementary approaches were similar to those in previous surveys. The safety and effectiveness of CAM treatments is often not well documented or studied, i.e., an insufficient evidence-base. Reasons may include a lack of funding and time, institutions willing to perform the studies, and regulatory issues. Generating a body of evidence from which conclusions can be drawn as to whether individual treatments are safe at effective at improving overall health (and for whom) is an ongoing area of development within the National Center for Complementary and Integrative Health.<sup>5</sup>

## Behavioral Health

Behavioral health refers to the connection between behaviors and the overall well-being of the body, mind, and spirit. It encompasses a wide range of activities, conditions, and treatment services that address mental health, substance use, and other health-related behaviors. This field includes the prevention, diagnosis, and treatment of mental disorders, emotional disturbances, and unhealthy behaviors, as well as the promotion of positive behavior changes to improve an individual's overall health and quality of life. Behavioral health professionals often include psychologists, psychiatrists, social workers, counselors, and addiction specialists.

## Treatments

Complementary and alternative medicine (CAM) treatments identified in this policy are not an exhaustive list, but rather, a list of example treatments where the evidence base is lacking:

- *Autogenous lymphocytic factor*
- *Colon hydrotherapy, irrigation, cleansing and lavage*
- *Intravenous infusion including:*
  - *Hydrogen peroxide*
  - *Micronutrient (Myers' cocktail)*

- *Vitamin C*
- *Manual and soft tissue therapies including:*
  - *Active release technique*
  - *Craniosacral therapy*
  - *Cupping*
  - *Graston technique*
  - *TuiNa*
- *Mesotherapy*
- *Oxygen therapy, including ozone therapy administered directly to the tissue, intravenously, or intramuscularly*
- *Placentophagy/placenta capsules*

## REGULATORY STATUS

### U.S. FOOD AND DRUG ADMINISTRATION (FDA)

Approval or clearance by the Food and Drug Administration (FDA) does not in itself establish medical necessity or serve as a basis for coverage. Therefore, this section is provided for informational purposes only.

## CLINICAL EVIDENCE AND LITERATURE REVIEW

### EVIDENCE REVIEW

A review of the ECRI, Hayes, Cochrane, and PubMed databases was conducted regarding the use of CAM treatments in general, and specifically those identified in this policy. Since the indications for treatment within this list is quite broad, the following review is focused on high-quality systematic reviews of the evidence identified through September 2024.

#### **Autogenous Lymphocytic Factor (ALF)**

Autogenous lymphocytic factor (ALF) is purported to boost immunity and eliminate risk future risk of disease that could be picked up from other processes that are not from placenta or other parts of the human.<sup>6</sup> ALF is generated from an individual's own blood.

No systematic reviews regarding the use of ALF as a treatment for any indication were identified. A single, nonrandomized study from 1998 was identified.<sup>7</sup> Three hundred fifteen individuals were studied, including 25 controls and 290 chemically sensitive immunocompromised patients. Conclusions regarding the efficacy and safety of ALF cannot be made from the existing evidence base.

#### **Colon Hydrotherapy, Colonic Irrigation, Colonic Cleansing, and Colonic Lavage**

Colon hydrotherapy is also known as colonics, colon cleanse, or colon irrigation and has evolved over centuries into the modern form of performing a wash of the colon or large intestine, using water to remove waste matter.<sup>8</sup> This section does include the use of colon cleansing prior to a medically indicated health screen or diagnostic study (e.g., colonoscopy).

A single systematic review was identified regarding the use of colonic cleansing for general health promotion in the lay population.<sup>9</sup> The authors conducted a narrative review of the existing evidence base, including publications from both traditional and CAM publications. Conclusions could not be drawn as the authors identified no methodologically rigorous controlled trials of colonic cleansing for general health promotion. The authors did report identifying numerous case studies and series describing adverse effects of colon cleansing.

### **Intravenous Infusion Including Micronutrients (Myers' Cocktail), Vitamin C and Hydrogen Peroxide**

Intravenous infusion micronutrient therapy (IVMT) involves the administration of vitamins and/or minerals with the goal of treating medical problems such as fatigue, infection, or cancer, or to improve and promote overall wellness. The Myers' cocktail is named for the late physician, John Myers, who administered a combination of magnesium chloride, calcium gluconate, thiamine, vitamin B6, vitamin B12, calcium pantothenate, vitamin B complex, vitamin C, and dilute hydrochloric acid to patients with problems such as fatigue, depression, chest pain, or heart palpitations in the 1970's. No record documents the exact doses of each constituent.

No systematic reviews regarding the use of intravenous micronutrient therapy including the Myers' cocktail were identified.

A systematic review of randomized controlled trials evaluating the protective role of intravenous vitamin C prior to percutaneous coronary intervention (PCI) was identified.<sup>10</sup> Meta-analyses were not performed. The Cochrane risk of bias tool for randomized trials was applied to assess bias amongst the eight included RCTs. Two trials did not report randomization strategy, though overall the authors reported risk of bias to be low. Sample sizes ranged from 21 to 532 in publications identified between 1997 and 2019. The authors reported that six types of outcomes (myocardial injury, antioxidant reservoir, ROS, inflammatory mediators, coronary perfusion index, endothelial dysfunction) showed statistically significant improvement, while three types of outcomes showed inconclusive associations (infarct size, coronary artery restenosis and cardiac contractility as assessed by LVEF). However, the overall heterogeneity of these eight trials significantly limits the ability to evaluate whether intravenous vitamin C prior to PCI has an overall health benefit. Doses varied across studies, as did timing of the intervention, and the variability of administration of other antioxidants and aspirin prior to PCI.

Intravenous hydrogen peroxide has also been investigated to treat bacterial or viral infections, migraines, chronic lung conditions, allergies and cancer.

No systematic reviews regarding the use of intravenous hydrogen peroxide as a treatment for any indication were identified. A case report was identified documenting the fatal administration of intravenous hydrogen peroxide given to an infant by mistake.<sup>11</sup>

## Manual and Soft Tissue Therapies

Various methods of bodywork from ancient Eastern medicine and modern-day techniques are applied with the intent of overall health promotion and healing ailments including acute and chronic pain.

Active release techniques were developed by an individual chiropractor who first published his work regarding this soft tissue method of relieving tension in the mid 1980's under the term myofascial release.<sup>12</sup> The methodology was later patented and adopted the current terminology. No systematic reviews were identified regarding the use of active release techniques for any indication.

Craniosacral therapy (CST) was developed in the 1970's by a doctor of osteopathy.<sup>13</sup> Practitioners of CST apply a small amount of pressure (5 grams) with the goal of releasing restrictions in the craniosacral system, thus aiding the body in healing pain and dysfunction associated with a wide array of disorders and injury. A Cochrane systematic review was identified regarding interventions for preventing and treating low-back and pelvic pain during pregnancy.<sup>14</sup> The authors reported finding low-level evidence that craniosacral therapy may improve pregnancy-related pelvic pain, though these findings were made from one single-center, single blind study with a sample of 123 women. Another systematic review with meta-analyses included 10 randomized controlled trials with a total of 681 patients with neck and back pain, migraine, headache, fibromyalgia, epicondylitis, and pelvic girdle pain.<sup>15</sup> Amongst the trials, no serious adverse events were reported, and pooled analysis from a subset of studies suggested that CST showed a significant greater effect of a small size directly after the intervention (2 RCTs, SMD = - 0.32, 95%CI = [- 0.61, -0.02], I2 = 0%, N = 183). When compared with sham manual and non-manual therapies, at 6-months follow-up CST was found to have significant medium effect size in favor of CST (2 RCTs, SMD = - 0.59, 95%CI = [- 0.99, - 0.19], I2 = 25%, N = 138). In sensitivity analyses, the findings were reported to be robust. The authors reported that more RCT following strict design protocol are needed to corroborate the effects identified these studies. No additional systematic reviews with meta-analyses were identified.

Cupping therapy dates back to ancient Egyptian, Chinese, and Middle Eastern cultures, documented in texts as early as 1,550 B.C.<sup>16</sup> Cups used in this technique may be made of glass, bamboo, earthenware or silicone, and typically 3-7 cups are applied wet or dry for up to three minutes. Cupping may be included with other therapies as a form of deep tissue massage with the aim of helping with pain, inflammation, blood flow, and relaxation. Studies of cupping have investigated the effects on acne<sup>17</sup>, fibromyalgia<sup>18</sup>, herpes zoster<sup>19</sup>, hypertension<sup>20</sup>, pain<sup>21-26</sup>, and numerous other indications<sup>27,28</sup>. Collectively, studies of this modality are difficult to draw conclusions from regarding long term overall health benefits due to heterogeneity in the design (e.g., cupping used in conjunction with other modalities, or cupping compared to shams). While some studies find significant benefit, others report no effect or very low-quality evidence from those that demonstrate benefit; beneficial effects are reported to be temporary, mild, or both. Overall, the evidence as to whether this is a beneficial treatment and for which patient populations is still lacking.

Instrument assisted soft tissue mobilization (IASTM) is a treatment applied to myofascial restrictions. By combining the application of the instruments and therapeutic exercise, the goal is to help break down

collagen cross-links (scar tissue) and increase blood flow and cellular activity. The Graston Technique® is one form of IASTM, and is a patented therapy developed by an amateur athlete who collaborated with medical personnel and researchers to develop a set of stainless steel instruments to assist with soft tissue lesions and fascial restrictions.<sup>29</sup> Three systematic reviews were identified; the use of IASTM is not supported by the current evidence base.<sup>30-32</sup>

TuiNa massage manipulation, pronounced twee-nah massage originated in ancient China and is believed to be the oldest system of bodywork. It's one of the four main branches of traditional Chinese medicine. It's based on the theory that imbalances of qi or vital life force or energy, can cause blockages or imbalances that lead to pain and illness. Practitioners use oscillating and pressure techniques such as acupressure, myofascial release and reflexology that differ in force and speed to massage muscles and tendons and uses manipulation to realign the body. Passive joint movements are used to restore function to muscles and joints. To enhance the effects, herbal poultices or compresses, lotions, and salves are used. A large body of systematic reviews of studies (many, RCT's) conducted in China and Korea were identified, evaluating the effects of tuina massage in pediatric and adult indications including, but limited to anorexia nervosa, chronic fatigue syndrome, hypertension, irritable bowel syndrome, and musculoskeletal disorders.<sup>23,33-47</sup> A Cochrane systematic review was also identified, evaluating manual methods of pain management in labor, which included tuina.<sup>48</sup> Collectively, these studies report the following:

- High or unclear risk of bias
- No symptom improvement
- No benefit over comparison group
- Results from methodology that is not reproducible
- In those reporting an improvement, authors state that it appears to be from very-low-quality evidence
- Need for additional high-quality studies

## **Acupuncture**

Acupuncture is a system of medical treatment and ideology that is the principle of applying small needles or pressure to specific points of the body.<sup>49</sup> The treatment originated in original Chinese medicine and has been used as a treatment option for several different diseases and symptoms.

Pain is one of the most common reasons for seeking acupuncture treatment.<sup>49</sup> Conditions range from chronic low back pain to chronic neck pain, tendinopathy, chronic cancer pain, etc. There have been numerous studies completed that demonstrate acupuncture has been successful and at treating these various conditions.<sup>50-58</sup>

Acupuncture is also frequently used in the treatment of nausea and/or vomiting, including chronic, postoperative, post chemotherapy, and pregnancy. Studies have found acupuncture to be a safe and effective treatment in a variety of underlying disorders.<sup>59-62</sup>

There have been several studies that indicate that acupuncture has been successful in reducing headache frequency and intensity for those with migraines and chronic headaches.<sup>49,63,64</sup> Acupuncture also resulted in fewer adverse effects than other therapies for this frequently pharmaceutically-resistant condition.

### **Mesotherapy**

Mesotherapy involves the subcutaneous injection of small quantities of substances, such as vitamins, silica, or lecithin, for the purpose of fat or wrinkle reduction.<sup>65</sup> No systematic reviews were identified regarding the use of mesotherapy for non-cosmetic (medical) indications.

### **Ozone therapy**

Ozone is a form of oxygen and may be referred to in the literature as “medical ozone”. Practitioners have reported the application of ozone therapy in gas and liquid form to treat numerous medical conditions and as a topical disinfectant. In the past decade, there have been over a dozen systematic reviews published regarding the use of ozone therapy as a treatment for a wide range of indications.

In 2019 the United States Food and Drug Administration issued a federal document in the Code of Federal Regulations regarding the dangers of ozone administration, including the following text:<sup>66</sup>

*(a) Ozone is a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy. In order for ozone to be effective as a germicide, it must be present in a concentration far greater than that which can be safely tolerated by man and animals.*

*(b) Although undesirable physiological effects on the central nervous system, heart, and vision have been reported, the predominant physiological effect of ozone is primary irritation of the mucous membranes. Inhalation of ozone can cause sufficient irritation to the lungs to result in pulmonary edema. The onset of pulmonary edema is usually delayed for some hours after exposure; thus, symptomatic response is not a reliable warning of exposure to toxic concentrations of ozone. Since olfactory fatigue develops readily, the odor of ozone is not a reliable index of atmospheric ozone concentration.*

### **Placentophagy/Placenta Capsules**

The act of postpartum women consuming their placenta (placentophagy) encapsulated, cooked and raw has been practiced in North America since the 1970’s as an act to prevent postpartum depression and other perceived health benefits.<sup>67</sup>

A Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report regarding a case of late-onset group B *Streptococcus agalactiae* (GBS) bacteremia in an infant in Oregon was published in 2017.<sup>68</sup> The infant’s illness was found to be attributable to high maternal colonization secondary to consumption of GBS-infected placental tissue. The mother ingested placenta capsules that were processed by a commercial company for consumption. According to the report, the commercial company states on their website that placenta is cleaned, sliced and dehydrated, then ground and placed into gelatin capsules and stored at room temperature. However, there are no standards that

exist for processing placenta for human consumption. The CDC report recommended that clinicians should inquire about a history of placenta ingestion in cases of late-onset GBS infection, and educate mothers interested in placenta encapsulation about the potential risks.

No systematic reviews were identified regarding placenta consumption for any indication.

### Lyme Disease Alternative Treatments

In 2015, Lantos et al. conducted a study to identify and characterize the range of unorthodox alternative therapies advertised to patients with a diagnosis of Lyme disease.<sup>69</sup> A review of evidence was then conducted for each alternative therapy to assess whether a scientific basis had been established for the effectiveness of the therapy.

The authors identified several broad categories of unconventional therapies for Lyme disease. These are summarized in the table below.

**Table 1. Examples of Alternative Therapies Marketed to Patients for the Treatment of Lyme Disease<sup>69</sup>**

Categories of Therapy	Examples
Oxygen	<ul style="list-style-type: none"> <li>- Hyperbaric oxygen</li> <li>- Hydrogen peroxide</li> <li>- Ozone</li> </ul>
Energy and radiation	<ul style="list-style-type: none"> <li>- Ultraviolet light</li> <li>- Photon therapy</li> <li>- “Cold” lasers</li> <li>- Saunas and steam rooms</li> <li>- “Rife” therapy (electromagnetic frequency treatments)</li> <li>- Magnets</li> </ul>
Metal/chelation	<ul style="list-style-type: none"> <li>- Mercury chelation and removal</li> <li>- Dimercaptosuccinic acid (DMSA)</li> <li>- 2,3-Dimercapto-1-propanesulfonic acid (DMPS)</li> <li>- Alpha lipoic acid (ALA)</li> <li>- Ethylene diamine tetraacetic acid (EDTA)</li> <li>- Removal of dental amalgam</li> <li>- Colloidal silver</li> <li>- Bismuth</li> </ul>
Nutritional supplements	<ul style="list-style-type: none"> <li>- Vitamins C and B12</li> <li>- Herbs</li> <li>- Garlic, cilantro, Chlorella, Sarsaparilla,</li> <li>- Andrographis, Turmeric, Olive leaf,</li> <li>- Cat’s claw</li> <li>- Burnt mugwort (moxibustion)</li> <li>- Glutathione</li> <li>- Fish oil</li> </ul>

	<ul style="list-style-type: none"> <li>- Magnesium</li> <li>- Salt</li> </ul>
Biological and pharmacologic	<ul style="list-style-type: none"> <li>- Urotherapy (urine ingestion)</li> <li>- Enemas</li> <li>- Bee venom</li> <li>- Hormonal therapy</li> <li>- Dihydroepiandrosterone, Pregnenolone, Cortisone, Hydrocortisone</li> <li>- Synthetic thyroid hormone</li> <li>- Lithium orotate</li> <li>- Olmesartan</li> <li>- Cholestyramine</li> <li>- Naltrexone</li> <li>- Sodium chlorite (bleach)</li> <li>- Intravenous immune globulin (IVIG)</li> <li>- Apheresis</li> <li>- Stem cell transplantation</li> </ul>

The authors identified no medical literature or scientific studies supporting the efficacy of any of the treatments listed above. Additionally, very few of these treatments were ever evaluated in any scientific studies, and those that were evaluated were done so in poorly designed studies. The authors concluded that “(t)he efficacy of these unconventional treatments for Lyme disease is not supported by scientific evidence, and in many cases they are potentially harmful.”<sup>69</sup>

## CLINICAL PRACTICE GUIDELINES

### National Institute for Health and Care Excellence (NICE)

NICE included acupuncture therapy in guidelines for pain including:

- Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic pain (2021)<sup>70</sup>
- Low back pain and sciatic in over 16s: assessment and management (2020)<sup>71</sup>

NICE also published a guideline on antenatal care in 2021.<sup>72</sup>

For pregnant women with moderate-to-severe nausea and vomiting:

- consider intravenous fluids, ideally on an outpatient basis
- consider acupressure as an adjunct treatment.

In 2021, NICE updated its guideline on the diagnosis and management of headaches.<sup>73</sup> Acupuncture is included as consideration for prophylactic treatment in chronic tension-type headaches, as well as for individuals with migraines in which topiramate and propranolol are unsuitable or ineffective.

### National Comprehensive Cancer Network (NCCN)

No clinical practice guidelines from the National Comprehensive Cancer Network were identified recommending any of the therapies in this policy.

### **Society of Obstetricians and Gynaecologists of Canada (SOGC)**

In 2019, the SOGC published a statement summarizing the reported benefits and harms of consumption of human placenta, including recent concerns from the U.S. Centers for Disease Control and Prevention about placental encapsulation.<sup>74</sup> SOGC stated that “there is no documented evidence of benefit for improved iron stores, mood, or lactation in any of the studies that meet critical review and standards of evidence. In addition to potential harm, there is now documented harm related to placental consumption. As such, in the absence of strong evidence showing benefits and absence of harm, the SOGC does not recommend the practice of placentophagy.”

### **Infectious Disease Society of America (IDSA)**

The 2006 IDSA guideline for the diagnosis, management, and prevention of Lyme disease recommends **against** the use of the following therapies for Lyme disease<sup>75</sup>:

- Excessive doses of antimicrobials
- Multiple, repeated courses of antimicrobials for the same episode of Lyme disease or an excessive duration of antimicrobial therapy
- Combination antimicrobial therapy
- Pulsed dosing (i.e., antibiotic therapy on some days but not on other days)
- First-generation cephalosporins, benzathine penicillin G, fluoroquinolones, carbapenems, vancomycin, metronidazole, tinidazole, trimethoprim-sulfamethoxazole, amantadine, ketolides, isoniazid, or fluconazole
- Empirical anti-babesiosis therapy in the absence of documentation of active babesiosis
- Anti-Bartonella therapies
- Hyperbaric oxygen therapy
- Fever therapy (with or without malaria induction)
- Intravenous immunoglobulin
- Ozone
- Cholestyramine
- Intravenous hydrogen peroxide
- Vitamins or nutritional managements
- Magnesium or bismuth injections

### **EVIDENCE SUMMARY**

Complementary and alternative medicine (CAM) are approaches to care that are not in the mainstream standard of care approach. Acupuncture (including dry needling), has been a commonly used treatment for a multitude of medical conditions historically and in modern times. Safety and effectiveness have been established for several conditions, and continues to expand with additional research. Currently,

there is sufficient evidence and clinical practice guidelines to support the use of acupuncture in the treatment of pain, nausea/vomiting, and headaches.

However, the safety and effectiveness of several individual CAM treatments are frequently not well supported by a sufficient evidence base. Research into these practices is an ongoing area of development. Some studies report benefits, though the size of the effect and time period associated with the effects are still unclear. No clinical practice guidelines based on research were identified specifically recommending CAM treatment, other than acupuncture. More research is needed with sufficient design to draw conclusions about overall benefits and safety for many CAM treatments.

## **HEALTH EQUITY CONSIDERATIONS**

The Centers for Disease Control and Prevention (CDC) defines health equity as the state in which everyone has a fair and just opportunity to attain their highest level of health. Achieving health equity requires addressing health disparities and social determinants of health. A health disparity is the occurrence of diseases at greater levels among certain population groups more than among others. Health disparities are linked to social determinants of health which are non-medical factors that influence health outcomes such as the conditions in which people are born, grow, work, live, age, and the wider set of forces and systems shaping the conditions of daily life. Social determinants of health include unequal access to health care, lack of education, poverty, stigma, and racism.

The U.S. Department of Health and Human Services Office of Minority Health calls out unique areas where health disparities are noted based on race and ethnicity. Providence Health Plan (PHP) regularly reviews these areas of opportunity to see if any changes can be made to our medical or pharmacy policies to support our members obtaining their highest level of health. Upon review, PHP creates a Coverage Recommendation (CORE) form detailing which groups are impacted by the disparity, the research surrounding the disparity, and recommendations from professional organizations. PHP Health Equity COREs are updated regularly and can be found online [here](#).

## **BILLING GUIDELINES AND CODING**

### **BILLING GUIDELINES**

#### **Therapeutic Phlebotomy**

Therapeutic phlebotomy (CPT 99195) may only be considered medically necessary when billed with the indications/diagnosis codes listed in the appendices below ([Appendix I](#)). Claims billed with a diagnosis code not listed here will be denied as “not medically necessary.”

#### **Acupuncture**

Acupuncture may only be considered medically necessary when billed with the indications/diagnosis codes listed in the appendices below ([Appendix II](#)). Claims billed with a diagnosis code not listed here will be denied as “not medically necessary.”

<b>CODES*</b>		
<b>CPT</b>	0736T	Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter
	96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hourcup
	96361	Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)
	96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
	96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
	96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)
	96368	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)
	96369	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); initial, up to 1 hour, including pump set-up and establishment of subcutaneous infusion site(s)
	96370	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
	96371	Subcutaneous infusion for therapy or prophylaxis (specify substance or drug); additional pump set-up with establishment of new subcutaneous infusion site(s) (List separately in addition to code for primary procedure)
	96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
	96373	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intra-arterial
	96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug
	96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)
	96376	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)
	96377	Application of on-body injector (includes cannula insertion) for timed subcutaneous injection
	97124	Therapeutic procedure, 1 or more areas, each 15 minutes; massage, including effleurage, petrissage and/or tapotement (stroking, compression, percussion)

97140	Manual therapy techniques (eg, mobilization/ manipulation, manual lymphatic drainage, manual traction), 1 or more regions, each 15 minutes
97810	Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
97811	Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with insertion of needle(s) (List separately in addition to code for primary procedure)
97813	Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient
97814	Acupuncture, 1 or more needles; with electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with insertion of needle(s) (List separately in addition to code for primary procedure)
98925	Osteopathic manipulative treatment (OMT); 1-2 body regions involved
98926	Osteopathic manipulative treatment (OMT); 3-4 body regions involved
98927	Osteopathic manipulative treatment (OMT); 5-6 body regions involved
98928	Osteopathic manipulative treatment (OMT); 7-8 body regions involved
98929	Osteopathic manipulative treatment (OMT); 9-10 body regions involved
99195	Phlebotomy, therapeutic (separate procedure)
99601	Home infusion/specialty drug administration, per visit (up to 2 hours)
99602	Home infusion/specialty drug administration, per visit (up to 2 hours); each additional hour (List separately in addition to code for primary procedure)
45399	Unlisted procedure, colon
96379	Unlisted therapeutic, prophylactic, or diagnostic intravenous or intra-arterial injection or infusion
97039	Unlisted modality (specify type and time if constant attendance)

**\*Coding Notes:**

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.
- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be **denied as not covered**. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, **prior authorization is recommended**.
- **See the non-covered and prior authorization lists on the Company [Medical Policy](#), [Reimbursement Policy](#), [Pharmacy Policy and Provider Information website](#) for additional information.**
- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

## REFERENCES

1. Centers for Medicare & Medicaid Services. Acupuncture for Chronic Lower Back Pain (cLBP). <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=373>. Published 2020. Accessed 4/29/2024.
2. National Cancer Institute. Complementary and Alternative Medicine. Updated: June 12, 2023. <https://www.cancer.gov/about-cancer/treatment/cam>. Accessed 9/18/2023.

3. National Institutes of Health. National Center for Complementary and Integrative Health (NCCIH). Complementary, Alternative, or Integrative Health: What's In a Name? Last Updated: April 2021. <https://www.nccih.nih.gov/health/complementary-alternative-or-integrative-health-whats-in-a-name>. Accessed 9/18/2023.
4. National Institutes of Health. National Center for Complementary and Integrative Health (NCCIH). The Use and Cost of Complementary Health Approaches in the United States. <https://www.nccih.nih.gov/about/the-use-and-cost-of-complementary-health-approaches-in-the-united-states>. Accessed 9/18/2023.
5. National Institutes of Health. National Center for Complementary and Integrative Health (NCCIH). NCCIH Strategic Plan FY 2021-2025. <https://www.nccih.nih.gov/about/nccih-strategic-plan-2021-2025>. Accessed 9/18/2023.
6. Environmental Health Center - Dallas. Immune Boosters <https://www.ehcd.com/immune-booster/>. Accessed 09/18/2023.
7. Griffiths BB, Rea WJ, Griffiths B, Pan Y. The role of the T lymphocytic cell cycle and an autogenous lymphocytic factor in clinical medicine. *Cytobios*. 1998;93(372):49-66.
8. Association of Registered Colon Hydrotherapists (ARCH). <http://www.colonic-association.org/about-colon-hydrotherapy/>. Accessed 09/18/2023.
9. Acosta RD, Cash BD. Clinical effects of colonic cleansing for general health promotion: a systematic review. *Am J Gastroenterol*. 2009;104(11):2830-2836; quiz 2837.
10. Khan SA, Bhattacharjee S, Ghani MOA, Walden R, Chen QM. Vitamin C for Cardiac Protection during Percutaneous Coronary Intervention: A Systematic Review of Randomized Controlled Trials. *Nutrients*. 2020;12(8).
11. Lubec B, Hayn M, Denk W, Bauer G. Brain lipid peroxidation and hydroxy radical attack following the intravenous infusion of hydrogen peroxide in an infant. *Free Radic Biol Med*. 1996;21(2):219-223.
12. Active Release Techniques. <https://www.activerelease.com/about.asp>. Accessed 09/18/2023.
13. Upledger Institute International | Discover CranioSacral Therapy. <https://www.upledger.com/therapies/index.php>. Accessed 09/18/2023.
14. Liddle SD, Pennick V. Interventions for preventing and treating low-back and pelvic pain during pregnancy. *Cochrane Database Syst Rev*. 2015(9):CD001139.
15. Haller H, Lauche R, Sundberg T, Dobos G, Cramer H. Craniosacral therapy for chronic pain: a systematic review and meta-analysis of randomized controlled trials. *BMC Musculoskelet Disord*. 2019;21(1):1.
16. WebMD. Cupping Therapy. Updated Nov 2, 2022. <https://www.webmd.com/balance/guide/cupping-therapy#1>. Accessed 09/18/2023.
17. Cao H, Yang G, Wang Y, et al. Complementary therapies for acne vulgaris. *Cochrane Database Syst Rev*. 2015;1:CD009436.
18. Cao H, Liu J, Lewith GT. Traditional Chinese Medicine for treatment of fibromyalgia: a systematic review of randomized controlled trials. *J Altern Complement Med*. 2010;16(4):397-409.
19. Cao H, Zhu C, Liu J. Wet cupping therapy for treatment of herpes zoster: a systematic review of randomized controlled trials. *Altern Ther Health Med*. 2010;16(6):48-54.
20. Lu S, Du S, Fish A, Tang C, Lou Q, Zhang X. Wet cupping for hypertension: a systematic review and meta-analysis. *Clin Exp Hypertens*. 2019;41(5):474-480.
21. Kim S, Lee SH, Kim MR, et al. Is cupping therapy effective in patients with neck pain? A systematic review and meta-analysis. *BMJ Open*. 2018;8(11):e021070.

22. Wang YT, Qi Y, Tang FY, et al. The effect of cupping therapy for low back pain: A meta-analysis based on existing randomized controlled trials. *J Back Musculoskelet Rehabil.* 2017;30(6):1187-1195.
23. Yuan QL, Guo TM, Liu L, Sun F, Zhang YG. Traditional Chinese medicine for neck pain and low back pain: a systematic review and meta-analysis. *PLoS One.* 2015;10(2):e0117146.
24. Kim JI, Lee MS, Lee DH, Boddy K, Ernst E. Cupping for treating pain: a systematic review. *Evid Based Complement Alternat Med.* 2011;2011:467014.
25. Wang YL, An CM, Song S, Lei FL, Wang Y. Cupping Therapy for Knee Osteoarthritis: A Synthesis of Evidence. *Complement Med Res.* 2018;25(4):249-255.
26. Wang L, Cai Z, Li X, Zhu A. Efficacy of cupping therapy on pain outcomes: an evidence-mapping study. *Front Neurol.* 2023;14:1266712.
27. Li JQ, Guo W, Sun ZG, et al. Cupping therapy for treating knee osteoarthritis: The evidence from systematic review and meta-analysis. *Complement Ther Clin Pract.* 2017;28:152-160.
28. Ma SY, Wang Y, Xu JQ, Zheng L. Cupping therapy for treating ankylosing spondylitis: The evidence from systematic review and meta-analysis. *Complement Ther Clin Pract.* 2018;32:187-194.
29. Graston Technique. <https://grastontechnique.com/>. Accessed 9/18/2023.
30. Seffrin CB, Cattano NM, Reed MA, Gardiner-Shires AM. Instrument-Assisted Soft Tissue Mobilization: A Systematic Review and Effect-Size Analysis. *J Athl Train.* 2019;54(7):808-821.
31. Nazari G, Bobos P, MacDermid JC, Birmingham T. The Effectiveness of Instrument-Assisted Soft Tissue Mobilization in Athletes, Participants Without Extremity or Spinal Conditions, and Individuals with Upper Extremity, Lower Extremity, and Spinal Conditions: A Systematic Review. *Arch Phys Med Rehabil.* 2019;100(9):1726-1751.
32. Cheatham SW, Lee M, Cain M, Baker R. The efficacy of instrument assisted soft tissue mobilization: a systematic review. *J Can Chiropr Assoc.* 2016;60(3):200-211.
33. Liang SB, Lai BY, Cao HJ, et al. Pediatric tuina for the treatment of anorexia in children under 14 years: a systematic review and meta-analysis of randomized controlled trials. *Complement Ther Med.* 2020;51:102411.
34. Huang F, Zhao S, Dai L, et al. Tuina for cervical vertigo: A systematic review and meta-analysis of randomized controlled trials. *Complement Ther Clin Pract.* 2020;39:101115.
35. Chen SC, Ho YS, Kwai-Ping Suen L, et al. Traditional Chinese medicine (TCM) massage for the treatment of congenital muscular torticollis (CMT) in infants and children: A systematic review and meta-analysis. *Complement Ther Clin Pract.* 2020;39:101112.
36. Wang H, Mo S, Yang L, et al. Effectiveness associated with different therapies for senile osteoporosis: a network Meta-analysis. *J Tradit Chin Med.* 2020;40(1):17-27.
37. Kim DY, Lee JS, Park SY, Kim SJ, Son CG. Systematic review of randomized controlled trials for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J Transl Med.* 2020;18(1):7.
38. Zheng H, Chen R, Zhao X, et al. Comparison between the Effects of Acupuncture Relative to Other Controls on Irritable Bowel Syndrome: A Meta-Analysis. *Pain Res Manag.* 2019;2019:2871505.
39. Di YM, Yang L, Shergis JL, et al. Clinical evidence of Chinese medicine therapies for depression in women during perimenopause and menopause. *Complement Ther Med.* 2019;47:102071.
40. Mo Z, Li D, Zhang R, Chang M, Yang B, Tang S. Comparisons of the Effectiveness and Safety of Tuina, Acupuncture, Traction, and Chinese Herbs for Lumbar Disc Herniation: A Systematic Review and Network Meta-Analysis. *Evid Based Complement Alternat Med.* 2019;2019:6821310.

41. Lee NW, Kim GH, Heo I, et al. Chuna (or Tuina) Manual Therapy for Musculoskeletal Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Evid Based Complement Alternat Med.* 2017;2017:8218139.
42. Tao WW, Jiang H, Tao XM, Jiang P, Sha LY, Sun XC. Effects of Acupuncture, Tuina, Tai Chi, Qigong, and Traditional Chinese Medicine Five-Element Music Therapy on Symptom Management and Quality of Life for Cancer Patients: A Meta-Analysis. *J Pain Symptom Manage.* 2016;51(4):728-747.
43. Yang X, Zhao H, Wang J. Chinese massage (Tuina) for the treatment of essential hypertension: a systematic review and meta-analysis. *Complement Ther Med.* 2014;22(3):541-548.
44. Cheng YH, Huang GC. Efficacy of massage therapy on pain and dysfunction in patients with neck pain: a systematic review and meta-analysis. *Evid Based Complement Alternat Med.* 2014;2014:204360.
45. Kong LJ, Fang M, Zhan HS, et al. Tuina-focused integrative chinese medical therapies for inpatients with low back pain: a systematic review and meta-analysis. *Evid Based Complement Alternat Med.* 2012;2012:578305.
46. Alraek T, Lee MS, Choi TY, Cao H, Liu J. Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review. *BMC Complement Altern Med.* 2011;11:87.
47. Wang MY, Tsai PS, Lee PH, Chang WY, Yang CM. Systematic review and meta-analysis of the efficacy of tuina for cervical spondylosis. *J Clin Nurs.* 2008;17(19):2531-2538.
48. Smith CA, Levett KM, Collins CT, Dahlen HG, Ee CC, Sukanuma M. Massage, reflexology and other manual methods for pain management in labour. *Cochrane Database Syst Rev.* 2018;3:CD009290.
49. Van Hal M, Dydyk AM, Green MS. Acupuncture. In: *StatPearls*. Treasure Island (FL) ineligible companies. Disclosure: Alexander Dydyk declares no relevant financial relationships with ineligible companies. Disclosure: Michael Green declares no relevant financial relationships with ineligible companies.: StatPearls Publishing  
Copyright © 2024, StatPearls Publishing LLC.; 2024.
50. Inc. H. Acupuncture for the Treatment of Pain. <https://evidence.hayesinc.com/report/dir.acup0003>. Published 2009. Accessed 9/12/2024.
51. Inc. H. Acupuncture for Treatment of Fibromyalgia. <https://evidence.hayesinc.com/report/dir.acupunctfibromyalgia4451>. Published 2022. Accessed 9/12/2024.
52. Inc. H. Acupuncture for the Treatment of Shoulder Pain or Chronic Neck Pain: A Review of Reviews. <https://evidence.hayesinc.com/report/dir.acupuncture1703>. Published 2022. Accessed 9/12/2024.
53. Inc. H. Comparative Effectiveness Review of Acupuncture for the Treatment of Chronic Lower Back Pain: A Review of Reviews. <https://evidence.hayesinc.com/report/dir.acupuncture1702>. Published 2022. Accessed 9/12/2024.
54. Inc. H. Acupuncture for Treatment of Postoperative Pain: A Review of Reviews. <https://evidence.hayesinc.com/report/dir.1701acup0004>. Published 2022. Accessed 9/12/2024.
55. Inc. H. Dry Needling for Mechanical Neck and/or Trapezius Muscle Pain in Adults. <https://evidence.hayesinc.com/report/dir.needling2835>. Published 2024. Accessed 9/12/2024.
56. Zhang Y, Zhang Y, Liu S, et al. Acupuncture for cancer pain: a scoping review of systematic reviews and meta-analyses. *Front Oncol.* 2023;13:1169458.
57. Yang J, Wahner-Roedler DL, Zhou X, et al. Acupuncture for palliative cancer pain management: systematic review. *BMJ Support Palliat Care.* 2021;11(3):264-270.

58. Trinh K, Belski N, Zhou F, Kuhad A, Luk D, Youn E. The Efficacy of Acupuncture on Foot and Ankle for Pain Intensity, Functional Status, and General Quality of Life in Adults: A Systematic Review. *Med Acupunct*. 2021;33(6):386-395.
59. Yan Y, López-Alcalde J, Zhang L, Siebenhüner AR, Witt CM, Barth J. Acupuncture for the prevention of chemotherapy-induced nausea and vomiting in cancer patients: A systematic review and meta-analysis. *Cancer Med*. 2023;12(11):12504-12517.
60. Huang WH, Zhang J, Ding SS, Xue JJ. Efficacy of acupuncture for nausea and vomiting after laparoscopic surgery: A systematic review and meta-analysis. *Asian J Surg*. 2023;46(10):4462-4464.
61. Tan MY, Shu SH, Liu RL, Zhao Q. The efficacy and safety of complementary and alternative medicine in the treatment of nausea and vomiting during pregnancy: A systematic review and meta-analysis. *Front Public Health*. 2023;11:1108756.
62. Inc. H. Acupuncture for the Prevention or Treatment of Nausea and Vomiting: A Review of Reviews. <https://evidence.hayesinc.com/report/dir.acup0001>. Published 2022. Accessed 9/12/2024.
63. Inc. H. Comparative Effectiveness Review of Acupuncture for the Treatment of Episodic and Chronic Tension-Type Headache and Episodic Migraine: A Review of Reviews. <https://evidence.hayesinc.com/report/dir.acup0004>. Published 2022. Accessed 9/12/2024.
64. Wang Y, Du R, Cui H, Zhang L, Yuan H, Zheng S. Acupuncture for acute migraine attacks in adults: a systematic review and meta-analysis. *BMJ Evid Based Med*. 2023;28(4):228-240.
65. van Dissel JT, Kuijper EJ. Rapidly growing mycobacteria: emerging pathogens in cosmetic procedures of the skin. *Clin Infect Dis*. 2009;49(9):1365-1368.
66. United States Food & Drug Administration | CFR - Code of Federal Regulations Title 21. Chapter I. Current as of Jun 7, 2023. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?fr=801.415>. Accessed 09/18/2023.
67. Coyle CW, Hulse KE, Wisner KL, Driscoll KE, Clark CT. Placentophagy: therapeutic miracle or myth? *Arch Womens Ment Health*. 2015;18(5):673-680.
68. Buser GL, Mato S, Zhang AY, Metcalf BJ, Beall B, Thomas AR. Notes from the Field: Late-Onset Infant Group B Streptococcus Infection Associated with Maternal Consumption of Capsules Containing Dehydrated Placenta - Oregon, 2016. *MMWR Morb Mortal Wkly Rep*. 2017;66(25):677-678.
69. Lantos PM, Shapiro ED, Auwaerter PG, et al. Unorthodox alternative therapies marketed to treat Lyme disease. *Clin Infect Dis*. 2015;60(12):1776-1782.
70. National Institute for Health and Care Excellence (NICE). Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. <https://www.nice.org.uk/guidance/ng193/chapter/Recommendations>. Published 2021. Accessed 9/12/2024.
71. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. <https://www.nice.org.uk/guidance/ng59>. Published 2020. Accessed 9/12/2024.
72. National Institute for Health and Care Excellence (NICE). Antenatal care. <https://www.nice.org.uk/guidance/ng201/chapter/Recommendations>. Published 2021. Accessed 9/12/2024.
73. National Institute for Health and Care Excellence (NICE). Headaches in over 12s: diagnosis and management. <https://www.nice.org.uk/guidance/cg150/chapter/Recommendations>. Published 2021. Accessed 9/12/2024.

74. Elwood C, Money D, van Schalkwyk J, Pakzad Z, Bos H, Giesbrecht E. No. 378-Placentophagy. *J Obstet Gynaecol Can.* 2019;41(5):679-682.
75. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis.* 2006;43(9):1089-1134.

## POLICY REVISION HISTORY

DATE	REVISION SUMMARY
2/2023	Converted to new policy template.
1/2024	Annual update. Added code 0736T
6/2024	Interim update. Acupuncture added with medically necessary criteria and diagnosis codes. Diagnosis codes moved to appendices.
11/2024	Annual review. No change to policy criteria.
1/2025	Q1 2025 code set update. Revised codes.
4/2025	Interim update. Add criterion VI. to address behavioral health treatments.

## APPENDICES

Diagnosis codes for the noted services which are considered medically necessary indications include but are not limited to any of the ICD-10 codes listed below.

**Appendix I:** Therapeutic phlebotomy (CPT 99195) may only be considered **medically necessary** when billed with the indications/diagnosis codes listed below.

CODE	DESCRIPTION
<b>Polycythemia Vera</b>	
D45	Polycythemia vera
D75.0	Familial erythrocytosis
<b>Hemochromatosis</b>	
E83.11	Hemochromatosis
E83.110	Hereditary hemochromatosis
E83.111	Hemochromatosis due to repeated red blood cell transfusions
E83.118	Other hemochromatosis
E83.119	Hemochromatosis, unspecified
<b>Iron Overload</b>	
D75.8	Other specified disease of blood and blood-forming organs
D75.89	Other specified disease of blood and blood-forming organs
E83.1	Disorders of iron metabolism
E83.10	Disorders of iron metabolism, unspecified
E83.19	Other disorders of iron metabolism
R79.0	Abnormal level of blood mineral
T45.4X1	Poisoning by iron and its compounds, accidental
T45.4X1A	Poisoning by iron and its compounds, accidental, initial encounter
T45.4X1D	Poisoning by iron and its compounds, accidental, subsequent encounter

T45.4X1S	Poisoning by iron and its compounds, accidental, sequela
T45.4X2	Poisoning by iron and its compounds, intentional self-harm
T45.4X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter
T45.4X2D	Poisoning by iron and its compounds, intentional self-harm, subsequent encounter
T45.4X2S	Poisoning by iron and its compounds, intentional self-harm, sequela
T45.4X3	Poisoning by iron and its compounds, assault
T45.4X3A	Poisoning by iron and its compounds, assault, initial encounter
T45.4X3D	Poisoning by iron and its compounds, assault, subsequent encounter
T45.4X3S	Poisoning by iron and its compounds, assault, sequela
T45.4X4	Poisoning by iron and its compounds, undetermined
T45.4X4A	Poisoning by iron and its compounds, undetermined, initial encounter
T45.4X4D	Poisoning by iron and its compounds, undetermined, subsequent encounter
T45.4X4S	Poisoning by iron and its compounds, undetermined, sequela
T45.4X5	Adverse effect of iron and its compounds
T45.4X5A	Adverse effect of iron and its compounds, initial encounter
T45.4X5D	Adverse effect of iron and its compounds, subsequent encounter
T45.4X5S	Adverse effect of iron and its compounds, sequela

### **Erythrocytosis**

C22.0	Liver cell carcinoma
C64	Malignant neoplasm of kidney, except renal pelvis
C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
D09.1	Carcinoma in situ of other and unspecified urinary organs
D09.10	Carcinoma in situ of unspecified urinary organ
D09.19	Carcinoma in situ of other urinary organs
D75.1	Secondary polycythemia
D75.8	Other specified disease of blood and blood-forming organs
D75.89	Other specified disease of blood and blood-forming organs

### **Porphyria**

E80.0	Hereditary erythropoietic porphyria
E80.1	Porphyria cutanea tarda
E80.2	Other and unspecified porphyria
E80.20	Unspecified porphyria
E80.29	Other porphyria

## **Appendix II: Medically necessary diagnoses for acupuncture.**

<b>CODE</b>	<b>DESCRIPTION</b>
G43.001- G43.919	Migraine
G44.201	Tension-type headache, unspecified, intractable
G44.209	Tension-type headache, unspecified, not intractable
G44.211	Episodic tension-type headache, intractable
G44.219	Episodic tension-type headache, not intractable

G44.221-	Chronic tension-type headache
G44.229	
G44.301-	Post traumatic headache
G44.329	
G89.11	Acute pain due to trauma
G89.12	Acute post-thoracotomy pain
G89.18	Other acute postprocedural pain
G89.21	Chronic pain due to trauma
G89.22	Chronic post-thoracotomy pain
G89.28	Other chronic postprocedural pain
G89.29	Other chronic pain
G89.3	Neoplasm related pain (acute) (chronic)
G89.4	Chronic pain syndrome
K91.0	Vomiting following gastrointestinal surgery
M16.0-	Osteoarthritis of hip
M16.9	
M17.0-	Osteoarthritis of knee
M17.9	
M18.0-	Osteoarthritis of first carpometacarpal joint
M18.9	
M19.011-	Other and unspecified osteoarthritis
M19.93	
M25.511	Pain in right shoulder
M25.512	Pain in left shoulder
M25.519	Pain in unspecified shoulder
M25.521	Pain in right elbow
M25.522	Pain in left elbow
M25.529	Pain in unspecified elbow
M25.531	Pain in right wrist
M25.532	Pain in left wrist
M25.539	Pain in unspecified wrist
M25.541	Pain in joints of right hand
M25.542	Pain in joints of left hand
M25.549	Pain in joints of unspecified hand
M25.551	Pain in right hip
M25.552	Pain in left hip
M25.559	Pain in unspecified hip
M25.561	Pain in right knee
M25.562	Pain in left knee
M25.569	Pain in unspecified knee
M25.571	Pain in right ankle and joints of right foot
M25.572	Pain in left ankle and joints of left foot
M25.579	Pain in unspecified ankle and joints of unspecified foot
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region

M47.12	Other spondylosis with myelopathy, cervical region
M47.13	Other spondylosis with myelopathy, cervicothoracic region
M47.16	Other spondylosis with myelopathy, lumbar region
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region
M47.22	Other spondylosis with radiculopathy, cervical region
M47.23	Other spondylosis with radiculopathy, cervicothoracic region
M47.24	Other spondylosis with radiculopathy, thoracic region
M47.25	Other spondylosis with radiculopathy, thoracolumbar region
M47.26	Other spondylosis with radiculopathy, lumbar region
M47.27	Other spondylosis with radiculopathy, lumbosacral region
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region
M47.891	Other spondylosis, occipito-atlanto-axial region
M47.892	Other spondylosis, cervical region
M47.893	Other spondylosis, cervicothoracic region
M47.894	Other spondylosis, thoracic region
M47.895	Other spondylosis, thoracolumbar region
M47.896	Other spondylosis, lumbar region
M47.897	Other spondylosis, lumbosacral region
M47.898	Other spondylosis, sacral and sacrococcygeal region
M48.01	Spinal stenosis, occipito-atlanto-axial region
M48.02	Spinal stenosis, cervical region
M48.03	Spinal stenosis, cervicothoracic region
M48.04	Spinal stenosis, thoracic region
M48.05	Spinal stenosis, thoracolumbar region
M48.061	Spinal stenosis, lumbar region without neurogenic claudication
M48.07	Spinal stenosis, lumbosacral region
M48.08	Spinal stenosis, sacral and sacrococcygeal region
M50.00	Cervical disc disorder with myelopathy, unspecified cervical region
M50.01	Cervical disc disorder with myelopathy, high cervical region
M50.020	Cervical disc disorder with myelopathy, mid-cervical region, unspecified level
M50.021	Cervical disc disorder at C4-C5 level with myelopathy
M50.022	Cervical disc disorder at C5-C6 level with myelopathy
M50.023	Cervical disc disorder at C6-C7 level with myelopathy
M50.03	Cervical disc disorder with myelopathy, cervicothoracic region

M50.11	Cervical disc disorder with radiculopathy, high cervical region
M50.120	Mid-cervical disc disorder, unspecified level
M50.121	Cervical disc disorder at C4-C5 level with radiculopathy
M50.122	Cervical disc disorder at C5-C6 level with radiculopathy
M50.123	Cervical disc disorder at C6-C7 level with radiculopathy
M50.13	Cervical disc disorder with radiculopathy, cervicothoracic region
M50.20	Other cervical disc displacement, unspecified cervical region
M50.21	Other cervical disc displacement, high cervical region
M50.220	Other cervical disc displacement, mid-cervical region, unspecified level
M50.221	Other cervical disc displacement at C4-C5 level
M50.222	Other cervical disc displacement at C5-C6 level
M50.223	Other cervical disc displacement at C6-C7 level
M50.23	Other cervical disc displacement, cervicothoracic region
M50.30	Other cervical disc degeneration, unspecified cervical region
M50.31	Other cervical disc degeneration, high cervical region
M50.320	Other cervical disc degeneration, mid-cervical region, unspecified level
M50.321	Other cervical disc degeneration at C4-C5 level
M50.322	Other cervical disc degeneration at C5-C6 level
M50.323	Other cervical disc degeneration at C6-C7 level
M50.33	Other cervical disc degeneration, cervicothoracic region
M51.06	Intervertebral disc disorders with myelopathy, lumbar region
M51.14	Intervertebral disc disorders with radiculopathy, thoracic region
M51.15	Intervertebral disc disorders with radiculopathy, thoracolumbar region
M51.16	Intervertebral disc disorders with radiculopathy, lumbar region
M51.17	Intervertebral disc disorders with radiculopathy, lumbosacral region
M51.24	Other intervertebral disc displacement, thoracic region
M51.25	Other intervertebral disc displacement, thoracolumbar region
M51.26	Other intervertebral disc displacement, lumbar region
M51.27	Other intervertebral disc displacement, lumbosacral region
M51.34	Other intervertebral disc degeneration, thoracic region
M51.35	Other intervertebral disc degeneration, thoracolumbar region
M51.36	Other intervertebral disc degeneration, lumbar region
M51.37	Other intervertebral disc degeneration, lumbosacral region
M51.84	Other intervertebral disc disorders, thoracic region
M51.85	Other intervertebral disc disorders, thoracolumbar region
M51.86	Other intervertebral disc disorders, lumbar region
M51.87	Other intervertebral disc disorders, lumbosacral region
M51.A1	Intervertebral annulus fibrosus defect, small, lumbar region
M51.A2	Intervertebral annulus fibrosus defect, large, lumbar region
M51.A4	Intervertebral annulus fibrosus defect, small, lumbosacral region
M51.A5	Intervertebral annulus fibrosus defect, large, lumbosacral region
M53.0	Cervicocranial syndrome

M53.1	Cervicobrachial syndrome
M53.3	Sacrococcygeal disorders, not elsewhere classified
M54.2	Cervicalgia
M54.30-	Sciatica
M54.32	
M54.40-	Lumbago with sciatica
M54.42	
M54.50	Low back pain, unspecified
M54.51	Vertebrogenic low back pain
M54.59	Other low back pain
M54.6	Pain in thoracic spine
M54.89	Other dorsalgia
M54.9	Dorsalgia, unspecified
M77.40	Metatarsalgia, unspecified foot
M77.41	Metatarsalgia, right foot
M77.42	Metatarsalgia, left foot
M79.11	Myalgia of mastication muscle
M79.12	Myalgia of auxillary muscles, head and neck
M79.18	Myalgia, other site
M79.2	Neuralgia and neuritis, unspecified
M79.601	Pain in right arm
M79.602	Pain in left arm
M79.603	Pain in arm, unspecified
M79.604	Pain in right leg
M79.605	Pain in left leg
M79.606	Pain in leg, unspecified
M79.621	Pain in right upper arm
M79.622	Pain in left upper arm
M79.629	Pain in unspecified upper arm
M79.631	Pain in right forearm
M79.632	Pain in left forearm
M79.639	Pain in unspecified forearm
M79.641	Pain in right hand
M79.642	Pain in left hand
M79.643	Pain in unspecified hand
M79.644	Pain in right finger(s)
M79.645	Pain in left finger(s)
M79.646	Pain in unspecified finger(s)
M79.651	Pain in right thigh
M79.652	Pain in left thigh
M79.659	Pain in unspecified thigh
M79.661	Pain in right lower leg
M79.662	Pain in left lower leg

M79.669	Pain in unspecified lower leg
M79.671	Pain in right foot
M79.672	Pain in left foot
M79.673	Pain in unspecified foot
M79.674	Pain in right toe(s)
M79.675	Pain in left toe(s)
M79.676	Pain in unspecified toe(s)
M79.7	Fibromyalgia
M99.01	Segmental and somatic dysfunction of cervical region
M99.02	Segmental and somatic dysfunction of thoracic region
M99.03	Segmental and somatic dysfunction of lumbar region
M99.04	Segmental and somatic dysfunction of sacral region
M99.05	Segmental and somatic dysfunction of pelvic region
M99.06	Segmental and somatic dysfunction of lower extremity
M99.07	Segmental and somatic dysfunction of upper extremity
M99.08	Segmental and somatic dysfunction of rib cage
M99.11	Subluxation complex (vertebral) of cervical region
M99.12	Subluxation complex (vertebral) of thoracic region
M99.13	Subluxation complex (vertebral) of lumbar region
M99.14	Subluxation complex (vertebral) of sacral region
M99.15	Subluxation complex (vertebral) of pelvic region
M99.16	Subluxation complex (vertebral) of lower extremity
M99.17	Subluxation complex (vertebral) of upper extremity
M99.18	Subluxation complex (vertebral) of rib cage
M99.21	Subluxation stenosis of neural canal of cervical region
M99.22	Subluxation stenosis of neural canal of thoracic region
M99.23	Subluxation stenosis of neural canal of lumbar region
M99.24	Subluxation stenosis of neural canal of sacral region
M99.25	Subluxation stenosis of neural canal of pelvic region
M99.26	Subluxation stenosis of neural canal of lower extremity
M99.27	Subluxation stenosis of neural canal of upper extremity
M99.28	Subluxation stenosis of neural canal of rib cage
M99.31	Osseous stenosis of neural canal of cervical region
M99.32	Osseous stenosis of neural canal of thoracic region
M99.33	Osseous stenosis of neural canal of lumbar region
M99.34	Osseous stenosis of neural canal of sacral region
M99.35	Osseous stenosis of neural canal of pelvic region
M99.36	Osseous stenosis of neural canal of lower extremity
M99.37	Osseous stenosis of neural canal of upper extremity
M99.38	Osseous stenosis of neural canal of rib cage
M99.41	Connective tissue stenosis of neural canal of cervical region
M99.42	Connective tissue stenosis of neural canal of thoracic region

M99.43	Connective tissue stenosis of neural canal of lumbar region
M99.44	Connective tissue stenosis of neural canal of sacral region
M99.45	Connective tissue stenosis of neural canal of pelvic region
M99.46	Connective tissue stenosis of neural canal of lower extremity
M99.47	Connective tissue stenosis of neural canal of upper extremity
M99.48	Connective tissue stenosis of neural canal of rib cage
M99.51	Intervertebral disc stenosis of neural canal of cervical region
M99.52	Intervertebral disc stenosis of neural canal of thoracic region
M99.53	Intervertebral disc stenosis of neural canal of lumbar region
M99.54	Intervertebral disc stenosis of neural canal of sacral region
M99.55	Intervertebral disc stenosis of neural canal of pelvic region
M99.56	Intervertebral disc stenosis of neural canal of lower extremity
M99.57	Intervertebral disc stenosis of neural canal of upper extremity
M99.58	Intervertebral disc stenosis of neural canal of rib cage
M99.61	Osseous and spondylosis stenosis of intervertebral foramina of cervical region
M99.62	Osseous and spondylosis stenosis of intervertebral foramina of thoracic region
M99.63	Osseous and spondylosis stenosis of intervertebral foramina of lumbar region
M99.64	Osseous and spondylosis stenosis of intervertebral foramina of sacral region
M99.65	Osseous and spondylosis stenosis of intervertebral foramina of pelvic region
M99.66	Osseous and spondylosis stenosis of intervertebral foramina of lower extremity
M99.67	Osseous and spondylosis stenosis of intervertebral foramina of upper extremity
M99.68	Osseous and spondylosis stenosis of intervertebral foramina of rib cage
M99.71	Connective tissue and disc stenosis of intervertebral foramina of cervical region
M99.72	Connective tissue and disc stenosis of intervertebral foramina of thoracic region
M99.73	Connective tissue and disc stenosis of intervertebral foramina of lumbar region
M99.74	Connective tissue and disc stenosis of intervertebral foramina of sacral region
M99.75	Connective tissue and disc stenosis of intervertebral foramina of pelvic region
M99.76	Connective tissue and disc stenosis of intervertebral foramina of lower extremity
M99.77	Connective tissue and disc stenosis of intervertebral foramina of upper extremity
M99.78	Connective tissue and disc stenosis of intervertebral foramina of rib cage
O21.0- O21.9	Excessive vomiting in pregnancy
R07.82	Intercostal pain
R07.9	Chest pain, unspecified
R11.0	Nausea
R11.10	Vomiting, unspecified
R11.11	Vomiting without nausea
R11.12	Projectile vomiting
R11.2	Nausea with vomiting, unspecified
R51.0	Headache with orthostatic component, not elsewhere classified
R51.9	Headache, unspecified
S13.4XXA	Sprain of ligaments of cervical spine, initial encounter
S13.4XXD	Sprain of ligaments of cervical spine, subsequent encounter

S13.4XXS	Sprain of ligaments of cervical spine, sequela
S13.8XXA	Sprain of joints and ligaments of other parts of neck, initial encounter
S13.8XXD	Sprain of joints and ligaments of other parts of neck, subsequent encounter
S13.8XXS	Sprain of joints and ligaments of other parts of neck, sequela
S16.1XXA	Strain of muscle, fascia and tendon at neck level, initial encounter
S16.1XXD	Strain of muscle, fascia and tendon at neck level, subsequent encounter
S16.1XXS	Strain of muscle, fascia and tendon at neck level, sequela
S16.8XXA	Other specified injury of muscle, fascia and tendon at neck level, initial encounter
S16.8XXD	Other specified injury of muscle, fascia and tendon at neck level, subsequent encounter
S16.8XXS	Other specified injury of muscle, fascia and tendon at neck level, sequela
S23.3XXA	Sprain of ligaments of thoracic spine, initial encounter
S23.3XXD	Sprain of ligaments of thoracic spine, subsequent encounter
S23.3XXS	Sprain of ligaments of thoracic spine, sequela
S23.8XXA	Sprain of other specified parts of thorax, initial encounter
S23.8XXD	Sprain of other specified parts of thorax, subsequent encounter
S23.8XXS	Sprain of other specified parts of thorax, sequela
S29.011A	Strain of muscle and tendon of front wall of thorax, initial encounter
S29.011D	Strain of muscle and tendon of front wall of thorax, subsequent encounter
S29.011S	Strain of muscle and tendon of front wall of thorax, sequela
S29.012A	Strain of muscle and tendon of back wall of thorax, initial encounter
S29.012D	Strain of muscle and tendon of back wall of thorax, subsequent encounter
S29.012S	Strain of muscle and tendon of back wall of thorax, sequela
S33.5XXA	Sprain of ligaments of lumbar spine, initial encounter
S33.5XXD	Sprain of ligaments of lumbar spine, subsequent encounter
S33.5XXS	Sprain of ligaments of lumbar spine, sequela
S33.6XXA	Sprain of sacroiliac joint, initial encounter
S33.6XXD	Sprain of sacroiliac joint, subsequent encounter
S33.6XXS	Sprain of sacroiliac joint, sequela
S33.8XXA	Sprain of other parts of lumbar spine and pelvis, initial encounter
S33.8XXD	Sprain of other parts of lumbar spine and pelvis, subsequent encounter
S33.8XXS	Sprain of other parts of lumbar spine and pelvis, sequela
S39.012A	Strain of muscle, fascia and tendon of lower back, initial encounter
S39.012D	Strain of muscle, fascia and tendon of lower back, subsequent encounter
S39.012S	Strain of muscle, fascia and tendon of lower back, sequela
S39.013A	Strain of muscle, fascia and tendon of pelvis, initial encounter
S39.013D	Strain of muscle, fascia and tendon of pelvis, subsequent encounter
S39.013S	Strain of muscle, fascia and tendon of pelvis, sequela
S43.491A	Other sprain of right shoulder joint, initial encounter
S43.491D	Other sprain of right shoulder joint, subsequent encounter
S43.491S	Other sprain of right shoulder joint, sequela
S43.492A	Other sprain of left shoulder joint, initial encounter
S43.492D	Other sprain of left shoulder joint, subsequent encounter

S43.492S	Other sprain of left shoulder joint, sequela
S43.81XA	Sprain of other specified parts of right shoulder girdle, initial encounter
S43.81XD	Sprain of other specified parts of right shoulder girdle, subsequent encounter
S43.81XS	Sprain of other specified parts of right shoulder girdle, sequela
S43.82XA	Sprain of other specified parts of left shoulder girdle, initial encounter
S43.82XD	Sprain of other specified parts of left shoulder girdle, subsequent encounter
S43.82XS	Sprain of other specified parts of left shoulder girdle, sequela
S46.811A	Strain of other muscles, fascia and tendons at shoulder and upper arm level, right arm, initial encounter
S46.811D	Strain of other muscles, fascia and tendons at shoulder and upper arm level, right arm, subsequent encounter
S46.811S	Strain of other muscles, fascia and tendons at shoulder and upper arm level, right arm, sequela
S46.812A	Strain of other muscles, fascia and tendons at shoulder and upper arm level, left arm, initial encounter
S46.812D	Strain of other muscles, fascia and tendons at shoulder and upper arm level, left arm, subsequent encounter
S46.812S	Strain of other muscles, fascia and tendons at shoulder and upper arm level, left arm, sequela
S53.411A	Radiohumeral (joint) sprain of right elbow, initial encounter
S53.411D	Radiohumeral (joint) sprain of right elbow, subsequent encounter
S53.411S	Radiohumeral (joint) sprain of right elbow, sequela
S53.412A	Radiohumeral (joint) sprain of left elbow, initial encounter
S53.412D	Radiohumeral (joint) sprain of left elbow, subsequent encounter
S53.412S	Radiohumeral (joint) sprain of left elbow, sequela
S53.419A	Radiohumeral (joint) sprain of unspecified elbow, initial encounter
S53.419D	Radiohumeral (joint) sprain of unspecified elbow, subsequent encounter
S53.419S	Radiohumeral (joint) sprain of unspecified elbow, sequela
S53.421A	Ulnohumeral (joint) sprain of right elbow, initial encounter
S53.421D	Ulnohumeral (joint) sprain of right elbow, subsequent encounter
S53.421S	Ulnohumeral (joint) sprain of right elbow, sequela
S53.422A	Ulnohumeral (joint) sprain of left elbow, initial encounter
S53.422D	Ulnohumeral (joint) sprain of left elbow, subsequent encounter
S53.422S	Ulnohumeral (joint) sprain of left elbow, sequela
S53.429A	Ulnohumeral (joint) sprain of unspecified elbow, initial encounter
S53.429D	Ulnohumeral (joint) sprain of unspecified elbow, subsequent encounter
S53.429S	Ulnohumeral (joint) sprain of unspecified elbow, sequela
S53.431A	Radial collateral ligament sprain of right elbow, initial encounter
S53.431D	Radial collateral ligament sprain of right elbow, subsequent encounter
S53.431S	Radial collateral ligament sprain of right elbow, sequela
S53.432A	Radial collateral ligament sprain of left elbow, initial encounter
S53.432D	Radial collateral ligament sprain of left elbow, subsequent encounter
S53.432S	Radial collateral ligament sprain of left elbow, sequela
S53.439A	Radial collateral ligament sprain of unspecified elbow, initial encounter

S53.439D	Radial collateral ligament sprain of unspecified elbow, subsequent encounter
S53.439S	Radial collateral ligament sprain of unspecified elbow, sequela
S53.441A	Ulnar collateral ligament sprain of right elbow, initial encounter
S53.441D	Ulnar collateral ligament sprain of right elbow, subsequent encounter
S53.441S	Ulnar collateral ligament sprain of right elbow, sequela
S53.442A	Ulnar collateral ligament sprain of left elbow, initial encounter
S53.442D	Ulnar collateral ligament sprain of left elbow, subsequent encounter
S53.442S	Ulnar collateral ligament sprain of left elbow, sequela
S53.449A	Ulnar collateral ligament sprain of unspecified elbow, initial encounter
S53.449D	Ulnar collateral ligament sprain of unspecified elbow, subsequent encounter
S53.449S	Ulnar collateral ligament sprain of unspecified elbow, sequela
S53.491A	Other sprain of right elbow, initial encounter
S53.491D	Other sprain of right elbow, subsequent encounter
S53.491S	Other sprain of right elbow, sequela
S53.492A	Other sprain of left elbow, initial encounter
S53.492D	Other sprain of left elbow, subsequent encounter
S53.492S	Other sprain of left elbow, sequela
S63.591A	Other specified sprain of right wrist, initial encounter
S63.591D	Other specified sprain of right wrist, subsequent encounter
S63.591S	Other specified sprain of right wrist, sequela
S63.592A	Other specified sprain of left wrist, initial encounter
S63.592D	Other specified sprain of left wrist, subsequent encounter
S63.592S	Other specified sprain of left wrist, sequela
S63.8X1A	Sprain of other part of right wrist and hand, initial encounter
S63.8X1D	Sprain of other part of right wrist and hand, subsequent encounter
S63.8X1S	Sprain of other part of right wrist and hand, sequela
S63.8X2A	Sprain of other part of left wrist and hand, initial encounter
S63.8X2D	Sprain of other part of left wrist and hand, subsequent encounter
S63.8X2S	Sprain of other part of left wrist and hand, sequela
S73.191A	Other sprain of right hip, initial encounter
S73.191D	Other sprain of right hip, subsequent encounter
S73.191S	Other sprain of right hip, sequela
S73.192A	Other sprain of left hip, initial encounter
S73.192D	Other sprain of left hip, subsequent encounter
S73.192S	Other sprain of left hip, sequela
S83.411A	Sprain of medial collateral ligament of right knee, initial encounter
S83.411D	Sprain of medial collateral ligament of right knee, subsequent encounter
S83.411S	Sprain of medial collateral ligament of right knee, sequela
S83.412A	Sprain of medial collateral ligament of left knee, initial encounter
S83.412D	Sprain of medial collateral ligament of left knee, subsequent encounter
S83.412S	Sprain of medial collateral ligament of left knee, sequela
S83.421A	Sprain of lateral collateral ligament of right knee, initial encounter

S83.421D	Sprain of lateral collateral ligament of right knee, subsequent encounter
S83.421S	Sprain of lateral collateral ligament of right knee, sequela
S83.422A	Sprain of lateral collateral ligament of left knee, initial encounter
S83.422D	Sprain of lateral collateral ligament of left knee, subsequent encounter
S83.422S	Sprain of lateral collateral ligament of left knee, sequela
S83.511A	Sprain of anterior cruciate ligament of right knee, initial encounter
S83.511D	Sprain of anterior cruciate ligament of right knee, subsequent encounter
S83.511S	Sprain of anterior cruciate ligament of right knee, sequela
S83.512A	Sprain of anterior cruciate ligament of left knee, initial encounter
S83.512D	Sprain of anterior cruciate ligament of left knee, subsequent encounter
S83.512S	Sprain of anterior cruciate ligament of left knee, sequela
S83.521A	Sprain of posterior cruciate ligament of right knee, initial encounter
S83.521D	Sprain of posterior cruciate ligament of right knee, subsequent encounter
S83.521S	Sprain of posterior cruciate ligament of right knee, sequela
S83.522A	Sprain of posterior cruciate ligament of left knee, initial encounter
S83.522D	Sprain of posterior cruciate ligament of left knee, subsequent encounter
S83.522S	Sprain of posterior cruciate ligament of left knee, sequela
S83.8X1A	Sprain of other specified parts of right knee, initial encounter
S83.8X1D	Sprain of other specified parts of right knee, subsequent encounter
S83.8X1S	Sprain of other specified parts of right knee, sequela
S83.8X2A	Sprain of other specified parts of left knee, initial encounter
S83.8X2D	Sprain of other specified parts of left knee, subsequent encounter
S83.8X2S	Sprain of other specified parts of left knee, sequela
S83.91XA	Sprain of unspecified site of right knee, initial encounter
S83.91XD	Sprain of unspecified site of right knee, subsequent encounter
S83.91XS	Sprain of unspecified site of right knee, sequela
S83.92XA	Sprain of unspecified site of left knee, initial encounter
S83.92XD	Sprain of unspecified site of left knee, subsequent encounter
S83.92XS	Sprain of unspecified site of left knee, sequela
S93.401A	Sprain of unspecified ligament of right ankle, initial encounter
S93.401D	Sprain of unspecified ligament of right ankle, subsequent encounter
S93.401S	Sprain of unspecified ligament of right ankle, sequela
S93.402A	Sprain of unspecified ligament of left ankle, initial encounter
S93.402D	Sprain of unspecified ligament of left ankle, subsequent encounter
S93.402S	Sprain of unspecified ligament of left ankle, sequela